Published in PLoS One on December 22, 2011
Prevalent and incident hepatitis C virus infection among HIV-infected men who have sex with men engaged in primary care in a Boston community health center. Clin Infect Dis (2013) 1.02
Many hepatitis C reinfections that spontaneously clear may be undetected: Markov-chain Monte Carlo analysis of observational study data. J R Soc Interface (2015) 0.78
Substance use, sexual behaviour and prevention strategies of Vancouver gay and bisexual men who recently attended group sex events. Cult Health Sex (2015) 0.77
Cytokine Response Associated with Hepatitis C Virus Clearance in HIV Coinfected Patients Initiating Peg Interferon-α Based Therapy. Mediterr J Hematol Infect Dis (2016) 0.76
EASL Clinical Practice Guidelines: management of hepatitis C virus infection. J Hepatol (2011) 6.63
Spontaneous viral clearance following acute hepatitis C infection: a systematic review of longitudinal studies. J Viral Hepat (2006) 5.10
Recent epidemic of acute hepatitis C virus in HIV-positive men who have sex with men linked to high-risk sexual behaviours. AIDS (2007) 4.40
An alternating least squares approach to inferring phylogenies from pairwise distances. Syst Biol (1997) 2.94
Increase in HCV incidence among men who have sex with men in Amsterdam most likely caused by sexual transmission. J Infect Dis (2007) 2.90
Acute hepatitis C virus infection in young adult injection drug users: a prospective study of incident infection, resolution, and reinfection. J Infect Dis (2009) 2.82
Influence of hepatitis C virus infection on HIV-1 disease progression and response to highly active antiretroviral therapy. J Infect Dis (2005) 2.73
Lack of evidence of sexual transmission of hepatitis C among monogamous couples: results of a 10-year prospective follow-up study. Am J Gastroenterol (2004) 2.58
Unsafe sex and increased incidence of hepatitis C virus infection among HIV-infected men who have sex with men: the Swiss HIV Cohort Study. Clin Infect Dis (2005) 2.35
A cluster of acute hepatitis C virus infection among men who have sex with men--results from contact tracing and public health implications. AIDS (2005) 2.34
Acute hepatitis C infection in HIV positive men who have sex with men in Paris, France, 2001-2004. Euro Surveill (2005) 2.20
The global spread of hepatitis C virus 1a and 1b: a phylodynamic and phylogeographic analysis. PLoS Med (2009) 2.06
High prevalence of hepatitis C virus infection among noninjecting drug users: association with sharing the inhalation implements of crack. Liver Int (2008) 2.04
Effective treatment of injecting drug users with recently acquired hepatitis C virus infection. Gastroenterology (2009) 1.99
Sexual transmission of hepatitis C virus among HIV-infected men who have sex with men--New York City, 2005-2010. MMWR Morb Mortal Wkly Rep (2011) 1.95
Acute hepatitis C in HIV-infected men who have sex with men: an emerging sexually transmitted infection. AIDS (2010) 1.81
Increased numbers of acute hepatitis C infections in HIV positive homosexual men; is sexual transmission feeding the increase? Sex Transm Infect (2004) 1.79
Liver fibrosis during an outbreak of acute hepatitis C virus infection in HIV-infected men: a prospective cohort study. J Infect Dis (2008) 1.78
Predicting spontaneous clearance of acute hepatitis C virus in a large cohort of HIV-1-infected men. Gut (2010) 1.77
Acute hepatitis C in HIV-infected individuals: recommendations from the European AIDS Treatment Network (NEAT) consensus conference. AIDS (2011) 1.59
Improving the diagnosis of acute hepatitis C virus infection with expanded viral load criteria. Clin Infect Dis (2009) 1.49
Sexually transmitted acute infection with a clustered genotype 4 hepatitis C virus in HIV-1-infected men and inefficacy of early antiviral therapy. AIDS (2006) 1.45
Trouble with bleeding: risk factors for acute hepatitis C among HIV-positive gay men from Germany--a case-control study. PLoS One (2011) 1.45
Increase in diagnosed newly acquired hepatitis C in HIV-positive men who have sex with men across London and Brighton, 2002-2006: is this an outbreak? Sex Transm Infect (2007) 1.44
Prevalence, incidence and risk factors for hepatitis C in homosexual men: data from two cohorts of HIV-negative and HIV-positive men in Sydney, Australia. Sex Transm Infect (2009) 1.35
Patterns and characteristics of hepatitis C transmission clusters among HIV-positive and HIV-negative individuals in the Australian trial in acute hepatitis C. Clin Infect Dis (2011) 1.32
Alarming incidence of hepatitis C virus re-infection after treatment of sexually acquired acute hepatitis C virus infection in HIV-infected MSM. AIDS (2011) 1.31
Impact of HIV on host-virus interactions during early hepatitis C virus infection. J Infect Dis (2008) 1.26
Sexual transmission of hepatitis C in MSM may not be confined to those with HIV infection. J Infect Dis (2008) 1.26
Reinfection with hepatitis C virus following sustained virological response in injection drug users. J Gastroenterol Hepatol (2010) 1.26
Intranasal transmission of hepatitis C virus: virological and clinical evidence. Clin Infect Dis (2008) 1.25
Treatment of acute hepatitis C in human immunodeficiency virus-infected patients: the HEPAIG study. Hepatology (2010) 1.15
Hepatitis C virus in the semen of men coinfected with HIV-1: prevalence and origin. AIDS (2005) 1.11
Prevalence of hepatitis C and hepatitis B infection in the HIV-infected population of France, 2004. Euro Surveill (2008) 1.11
Expertise of French laboratories in detection, genotyping, and quantification of hepatitis C virus RNA in serum. J Clin Microbiol (2004) 0.86
A relative profile of HIV-negative users of French websites for men seeking men and predictors of their regular risk taking: a comparison with HIV-positive users. AIDS Care (2011) 0.86
Sexually transmitted HCV infection and reinfection in HIV-infected homosexual men. Gastroenterol Clin Biol (2009) 0.86
Sexually transmitted reinfection with a new hepatitis C genotype during pegylated interferon and ribavirin therapy. AIDS (2005) 0.82
Risky sexual behavior, bleeding caused by intimate partner violence, and hepatitis C virus infection in patients of a sexually transmitted disease clinic. Am J Public Health (2009) 0.82
Telaprevir for retreatment of HCV infection. N Engl J Med (2011) 10.48
Telaprevir and peginterferon with or without ribavirin for chronic HCV infection. N Engl J Med (2009) 10.21
Triple therapy in treatment-experienced patients with HCV-cirrhosis in a multicentre cohort of the French Early Access Programme (ANRS CO20-CUPIC) - NCT01514890. J Hepatol (2013) 5.64
FIB-4: an inexpensive and accurate marker of fibrosis in HCV infection. comparison with liver biopsy and fibrotest. Hepatology (2007) 5.53
A Trial of Early Antiretrovirals and Isoniazid Preventive Therapy in Africa. N Engl J Med (2015) 5.30
Ribavirin for chronic hepatitis E virus infection in transplant recipients. N Engl J Med (2014) 4.70
CD4-guided structured antiretroviral treatment interruption strategy in HIV-infected adults in west Africa (Trivacan ANRS 1269 trial): a randomised trial. Lancet (2006) 4.06
Prevalence of resistance to nevirapine in mothers and children after single-dose exposure to prevent vertical transmission of HIV-1: a meta-analysis. Int J Epidemiol (2007) 3.69
Clinical practice. Infective endocarditis. N Engl J Med (2013) 3.67
Brief communication: the relationship of regression of cirrhosis to outcome in chronic hepatitis C. Ann Intern Med (2008) 3.54
Transfer and evaluation of an automated, low-cost real-time reverse transcription-PCR test for diagnosis and monitoring of human immunodeficiency virus type 1 infection in a West African resource-limited setting. J Clin Microbiol (2005) 3.36
Nodular regenerative hyperplasia is a new cause of chronic liver disease in HIV-infected patients. AIDS (2007) 3.25
Boceprevir versus placebo with pegylated interferon alfa-2b and ribavirin for treatment of hepatitis C virus genotype 1 in patients with HIV: a randomised, double-blind, controlled phase 2 trial. Lancet Infect Dis (2013) 3.17
Population-based HIV-1 incidence in France, 2003-08: a modelling analysis. Lancet Infect Dis (2010) 3.01
A systematic review of hepatitis C virus epidemiology in Europe, Canada and Israel. Liver Int (2011) 2.77
Impact of HIV-1 genetic diversity on plasma HIV-1 RNA Quantification: usefulness of the Agence Nationale de Recherches sur le SIDA second-generation long terminal repeat-based real-time reverse transcriptase polymerase chain reaction test. J Acquir Immune Defic Syndr (2007) 2.72
Outbreak of Shiga toxin-producing Escherichia coli O104:H4 associated with organic fenugreek sprouts, France, June 2011. Clin Infect Dis (2012) 2.71
Determinants of immune reconstitution inflammatory syndrome in HIV type 1-infected patients with tuberculosis after initiation of antiretroviral therapy. Clin Infect Dis (2004) 2.56
Extraordinary heterogeneity of virological outcomes in patients receiving highly antiretroviral therapy and monitored with the World Health Organization public health approach in sub-saharan Africa and southeast Asia. Clin Infect Dis (2013) 2.53
SAFE biopsy: a validated method for large-scale staging of liver fibrosis in chronic hepatitis C. Hepatology (2009) 2.45
Evidence for an antagonist form of the chemokine CXCL10 in patients chronically infected with HCV. J Clin Invest (2010) 2.43
"A La Carte" treatment of portal hypertension: Adapting medical therapy to hemodynamic response for the prevention of bleeding. Hepatology (2002) 2.37
Brief report: prevalence of antineutrophil cytoplasmic antibodies in infective endocarditis. Arthritis Rheumatol (2014) 2.24
Treatment of chronic hepatitis C in sickle cell disease and thalassaemic patients with interferon and ribavirin. Eur J Gastroenterol Hepatol (2009) 2.24
Predictors of virological rebound in HIV-1-infected patients initiating a protease inhibitor-containing regimen. AIDS (2002) 2.21
Prolonged valproic acid treatment does not reduce the size of latent HIV reservoir. AIDS (2008) 2.21
Efficacy of the protease inhibitor BI 201335, polymerase inhibitor BI 207127, and ribavirin in patients with chronic HCV infection. Gastroenterology (2011) 2.16
Distinct genetic loci control plasma HIV-RNA and cellular HIV-DNA levels in HIV-1 infection: the ANRS Genome Wide Association 01 study. PLoS One (2008) 2.14
Frequent occurrence of chronic hepatitis B virus infection among West African HIV type-1-infected children. Clin Infect Dis (2008) 2.12
IL28B alleles associated with poor hepatitis C virus (HCV) clearance protect against inflammation and fibrosis in patients infected with non-1 HCV genotypes. Hepatology (2011) 2.11
Evidence of a large, international network of HCV transmission in HIV-positive men who have sex with men. Gastroenterology (2009) 2.10
Gag mutations strongly contribute to HIV-1 resistance to protease inhibitors in highly drug-experienced patients besides compensating for fitness loss. PLoS Pathog (2009) 2.06
Sustained virologic response rates with telaprevir by response after 4 weeks of lead-in therapy in patients with prior treatment failure. J Hepatol (2012) 2.05
Benefits associated with antiviral treatment in kidney allograft recipients with chronic hepatitis B virus infection. J Hepatol (2012) 2.03
Noninvasive in vivo liver fibrosis evaluation using supersonic shear imaging: a clinical study on 113 hepatitis C virus patients. Ultrasound Med Biol (2011) 2.02
CD4 cell count and HIV DNA level are independent predictors of disease progression after primary HIV type 1 infection in untreated patients. Clin Infect Dis (2006) 2.02
Care of patients coinfected with HIV and hepatitis C virus: 2007 updated recommendations from the HCV-HIV International Panel. AIDS (2007) 2.00
Preeminence of Staphylococcus aureus in infective endocarditis: a 1-year population-based survey. Clin Infect Dis (2012) 1.97
AS03-adjuvanted versus non-adjuvanted inactivated trivalent influenza vaccine against seasonal influenza in elderly people: a phase 3 randomised trial. Lancet Infect Dis (2013) 1.95
Antimicrobial resistance in commensal flora of pig farmers. Emerg Infect Dis (2004) 1.95
CD8+ T cells specific for EBV, cytomegalovirus, and influenza virus are activated during primary HIV infection. J Immunol (2004) 1.93
Maternal 12-month response to antiretroviral therapy following prevention of mother-to-child transmission of HIV type 1, Ivory Coast, 2003-2006. Clin Infect Dis (2008) 1.90
LTR real-time PCR for HIV-1 DNA quantitation in blood cells for early diagnosis in infants born to seropositive mothers treated in HAART area (ANRS CO 01). J Med Virol (2009) 1.88
Universal antiretroviral therapy for pregnant and breast-feeding HIV-1-infected women: towards the elimination of mother-to-child transmission of HIV-1 in resource-limited settings. Clin Infect Dis (2009) 1.88
Mortality related to chronic hepatitis B and chronic hepatitis C in France: evidence for the role of HIV coinfection and alcohol consumption. J Hepatol (2007) 1.87
Hepatitis E in the south west of France in individuals who have never visited an endemic area. J Med Virol (2004) 1.85
Fibrinogen and fibronectin binding cooperate for valve infection and invasion in Staphylococcus aureus experimental endocarditis. J Exp Med (2005) 1.85
High prevalence of anti-hepatitis E virus antibodies in blood donors from South West France. J Med Virol (2008) 1.84
Characteristics and outcome of diffuse large B-cell lymphoma in hepatitis C virus-positive patients in LNH 93 and LNH 98 Groupe d'Etude des Lymphomes de l'Adulte programs. J Clin Oncol (2006) 1.83
Genome-wide association study of spontaneous resolution of hepatitis C virus infection: data from multiple cohorts. Ann Intern Med (2013) 1.82
Food-grade bacteria expressing elafin protect against inflammation and restore colon homeostasis. Sci Transl Med (2012) 1.73
Field evaluation of a rapid human immunodeficiency virus (HIV) serial serologic testing algorithm for diagnosis and differentiation of HIV type 1 (HIV-1), HIV-2, and dual HIV-1-HIV-2 infections in West African pregnant women. J Clin Microbiol (2004) 1.73
Genetics of dopamine receptors and drug addiction: a comprehensive review. Behav Pharmacol (2009) 1.72
Trends in virological and clinical outcomes in individuals with HIV-1 infection and virological failure of drugs from three antiretroviral drug classes: a cohort study. Lancet Infect Dis (2011) 1.68
Potency, safety, and pharmacokinetics of the NS3/4A protease inhibitor BI201335 in patients with chronic HCV genotype-1 infection. J Hepatol (2010) 1.63
French national sentinel survey of antiretroviral drug resistance in patients with HIV-1 primary infection and in antiretroviral-naive chronically infected patients in 2001-2002. J Acquir Immune Defic Syndr (2005) 1.63
Viral hepatitis in solid organ transplantation other than liver. J Hepatol (2011) 1.61
Performance of a predictive rule to distinguish bacterial and viral meningitis. J Infect (2006) 1.61
Telaprevir for HIV/hepatitis C virus-coinfected patients failing treatment with pegylated interferon/ribavirin (ANRS HC26 TelapreVIH): an open-label, single-arm, phase 2 trial. Clin Infect Dis (2014) 1.58
Tracing the HIV-1 subtype B mobility in Europe: a phylogeographic approach. Retrovirology (2009) 1.58
HBV and HCV prevalence and viraemia in HIV-positive and HIV-negative pregnant women in Abidjan, Côte d'Ivoire: the ANRS 1236 study. J Med Virol (2004) 1.55
Efficacy and pharmacodynamics of simulated human-like treatment with levofloxacin on experimental pneumonia induced with penicillin-resistant pneumococci with various susceptibilities to fluoroquinolones. J Antimicrob Chemother (2002) 1.55
Replication-competent HIV strains infect HIV controllers despite undetectable viremia (ANRS EP36 study). AIDS (2007) 1.53
Sarcopenia predicts early dose-limiting toxicities and pharmacokinetics of sorafenib in patients with hepatocellular carcinoma. PLoS One (2012) 1.53
The lymphocyte HIV reservoir in patients on long-term HAART is a memory of virus evolution. AIDS (2004) 1.52
Prognostic value of skin manifestations of infective endocarditis. JAMA Dermatol (2014) 1.51
Risk factors for virological failure and subtherapeutic antiretroviral drug concentrations in HIV-positive adults treated in rural northwestern Uganda. BMC Infect Dis (2009) 1.50
Low-dose peginterferon alfa-2a is safe and produces a sustained virologic response in patients with chronic hepatitis C and end-stage renal disease. Clin Gastroenterol Hepatol (2010) 1.49
Altered CD4+ T cell homing to the gut impairs mucosal immune reconstitution in treated HIV-infected individuals. J Clin Invest (2011) 1.49
Dual role of CCR2 in the constitution and the resolution of liver fibrosis in mice. Am J Pathol (2009) 1.49
Treatment of hepatitis C virus in human immunodeficiency virus infected patients in "real life": modifications in two large surveys between 2004 and 2006. J Hepatol (2007) 1.48
Impact of cytomorphological detection of circulating tumor cells in patients with liver cancer. Hepatology (2004) 1.48
New model of ventilator-associated pneumonia in immunocompetent rabbits. Crit Care Med (2002) 1.47
Hepatitis E is an autochthonous disease in industrialized countries. Analysis of 23 patients in South-West France over a 13-month period and comparison with hepatitis A. Gastroenterol Clin Biol (2006) 1.47
Ten-year incidence and risk factors of bone fractures in a cohort of treated HIV1-infected adults. AIDS (2009) 1.46
Sexually transmitted acute infection with a clustered genotype 4 hepatitis C virus in HIV-1-infected men and inefficacy of early antiviral therapy. AIDS (2006) 1.45
Histopathologic efficacy of ribavirin monotherapy in kidney allograft recipients with chronic hepatitis C. Transplantation (2004) 1.45
Systematic evaluation and description of anal pathology in HIV-infected patients during the HAART era. Dis Colon Rectum (2009) 1.45
HIV-1 resistant strains acquired at the time of primary infection massively fuel the cellular reservoir and persist for lengthy periods of time. AIDS (2006) 1.45
Ribavirin therapy inhibits viral replication on patients with chronic hepatitis e virus infection. Gastroenterology (2010) 1.44
Penetration of enfuvirtide, tenofovir, efavirenz, and protease inhibitors in the genital tract of HIV-1-infected men. AIDS (2004) 1.44
Prevalence of hepatitis B and hepatitis C virus infections in France in 2004: social factors are important predictors after adjusting for known risk factors. J Med Virol (2010) 1.43
Influenza vaccination coverage against seasonal and pandemic influenza and their determinants in France: a cross-sectional survey. BMC Public Health (2011) 1.43
Evidence of genotypic resistance diversity of archived and circulating viral strains in blood and semen of pre-treated HIV-infected men. AIDS (2004) 1.42
Homeostasis model assessment of insulin resistance does not seem to predict response to telaprevir in chronic hepatitis C in the REALIZE trial. Hepatology (2013) 1.41
Does IV Iron Induce Plasma Oxidative Stress in Critically Ill Patients? A Comparison With Healthy Volunteers. Crit Care Med (2016) 1.39
Patient and physician preferences for the treatment of chronic hepatitis C virus infections: does the perspective matter? Eur J Gastroenterol Hepatol (2015) 1.39
Prevalence of mixed cryoglobulins in relation to CD4 cell count among patients coinfected with HIV and hepatitis C virus. Clin Infect Dis (2004) 1.39
Spontaneous control of viral replication during primary HIV infection: when is "HIV controller" status established? Clin Infect Dis (2009) 1.35
Safety and reactogenicity profile of an adjuvanted H5N1 pandemic candidate vaccine in adults within a phase III safety trial. Vaccine (2008) 1.35